(redirected from proprietary medicine)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to proprietary medicine: Conventional medicine
References in periodicals archive ?
HONG KONG, May 2, 2019 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced a positive profit alert.
Hong Kong Customs arrested a salesman of a medicine shop suspected to have applied a false trade description in the course of selling a proprietary medicine, in contravention of the Trade Descriptions Ordinance (TDO).
The drug, the second proprietary medicine the regulatory agency has approved for the company this year, will be available in 5-, 7.5-, 10- and 15-mg.
He said that he would also continue to promote the use of Information Communication Technology (ICT) in the regulatory processes and give attention to the regulation of pharmacy technicians and patent and proprietary medicine vendors.
Revenue from the Proprietary Medicine segment achieved a year-on-year growth of 21.3% to HK$192.2 million.
The commander expressed the worry during a one-day sensitisation programme in which his agency collaborated with the Nigeria Association of Patent and Proprietary Medicine Dealers NAPPMED to sensitise and reduce abuse among young people and women in Yobe South Senatorial District of the State over the weekend.
Shri Shripad Yesso Naik, Minister of State (I/C) for AYUSH launched Elixir for Life, an Ayurvedic Proprietary Medicine at a function here today.
By the mid-1960s Combe had earned the respect of his colleagues in the proprietary medicine industry, many from much larger companies, who elected him chairman of the Proprietary Association, later known as the Nonprescription Drug Manufacturers Association and subsequently the Consumer Healthcare Products Association.
Revenue from the Proprietary Medicine segment witnessed a significant 76.2% growth to HK$121.2 million, attributable to the robust sales performance of Ho Chai Kung, a long-standing household brand that the Group acquired in January 2017, which contributed HK$45.2 million to the segmental revenue, plus the strengthening sales of Po Chai Pills and Tong Tai Chung Woodlok Oil.
The net proceeds of HK$490 million from the subscriptions are intended for a) funding potential acquisitions or forming strategic alliances in the Asia Pacific region with a view to expanding the Group's geographical reach and market presence for its generic drug and proprietary medicine businesses; and b) supporting in-licensing and direct investment on technologically-oriented bio-pharmaceutical projects to contemplate an entry into the innovation-driven therapeutic areas.
Revenue from the Proprietary Medicine segment recorded a year-on-year growth of 13.9% to HK$158.4 million.
The second platform of proprietary medicines being developed by RespireRx are ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors.

Full browser ?